Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K16/10 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/195136DEVICES FOR DETECTING ANTIBODIES TO CORONAVIRUS ANTIGENS
WO 30.09.2021
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2021/023762 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor FELGNER, Phillip L.
In alternative embodiments, provided are multiplexed systems, compositions, including products of manufacture such as arrays, microarrays and biochips, and kits, and methods, for detecting presence of a coronavirus in a sample, or to detect a coronavirus, e.g., COVID-19, infection. In alternative embodiments, provided are methods for detecting the presence of a coronavirus infection in an individual. In alternative embodiments, provided are vaccines and methods for using them to prevent, mitigate or lessen to effects of, or treat a coronavirus infection in an individual.
2.WO/2021/206638VACCINE AND/OR ANTIBODY FOR VIRAL INFECTION
WO 14.10.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/SG2021/050197 Applicant INTRA-IMMUSG PRIVATE LIMITED Inventor ZENG, Qi
The present invention relates to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) N-protein and/or an immunogenic fragment thereof and uses thereof. The invention also includes a nucleic acid molecule encoding the SARS-CoV-2 N-protein and/or an immunogenic fragment thereof; and uses thereof. The SARS-CoV-2 N protein and/or immunogenic fragment thereof may be produced by recombinant DNA technology or may be chemically synthesised. In particular, the SARS-CoV-2 N-protein and/or an immunogenic fragment thereof and/or nucleic acid molecule encoding the SARS-CoV-2 N-protein and immunogenic may be for use as a vaccine. The invention further includes an antibody capable of binding to the SARS-CoV-2 N-protein or antigen-binding fragment thereof and uses thereof.
3.2193802Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
EP 09.06.2010
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No 10151641 Applicant NEW YORK BLOOD CT INC Inventor JIANG SHIBO
An isolated neutralising monoclonal antibody capable of binding to the receptor-binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) wherein the antibody is produced by Hybridoma 30F9 with ATCC Accession No. PTA-6523.
4.3101131COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS­COV-2 VACCINES
CA 31.07.2021
Int.Class C12N 15/15
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
15Protease inhibitors, e.g. antithrombin, antitrypsin, hirudin
Appl.No 3101131 Applicant JANSSEN PHARMACEUTICALS, INC. Inventor

P217625CA00 CR U6043CAN P1
- 269 -
COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS
INFECTION - SARS-COV-2 VACCINES
Abstract
The invention relates to immunogenic compositions and vaccines containing a
coronavirus
(e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein
or a
polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV;
SARS-CoV-
2)) protein and uses thereof. The invention also provides methods of treating
and/or
preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2))
infection
by administering an immunogenic composition or vaccine to a subject (e.g., a
human). The
invention also provides methods of detecting and/or monitoring a protective
anti-
coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody
response (e.g.,
anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response,
e.g., anti-
Spike antibody response, e.g., anti-Spike neutralizing antibody response). The
present
invention relates to isolated nucleic and/or recombinant nucleic acid encoding
a
coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the
coronavirus S
proteins, as well as to the use of the nucleic acids and/or proteins thereof
in vaccines.
<1093966>
Date Recue/Date Received 2020-11-28

5.WO/2021/186190CORONAVIRUS ANTIBODY
WO 23.09.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/GB2021/050685 Applicant IMPERIAL COLLEGE INNOVATIONS LIMITED Inventor XU, Xiao-Ning
An antibody or antigen-binding fragment thereof is described which binds to the spike protein S2 domain of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome-related coronavirus (MERS-CoV) and/ or severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). The antibodies can be used in the diagnosis and treatment of coronavirus infection. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions, diagnostic compositions, and kits. The invention also extends to methods of making and using the antibodies, for example in the diagnosis and therapy of coronavirus infections.
6.WO/2021/203053IMMUNOTHERAPY TARGETING A CONSERVED REGION IN SARS CORONAVIRUSES
WO 07.10.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/025653 Applicant VIR BIOTECHNOLOGY, INC. Inventor CORTI, Davide
The present disclosure provides a conserved target region of a SARS coronavirus receptor binding domain (RBD). Also provided are antibodies and antigen-binding fragments thereof that are capable of bind in a target region, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are immunogenic compositions derived from a target region, and methods of using the same to, for example, treat or prevent a sarbecovirus infection.
7.2009201478The severe acute respiratory syndrome coronavirus
AU 07.05.2009
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 2009201478 Applicant Novartis Vaccines and Diagnostics, Inc. Inventor
An outbreak of a virulent respiratory virus, now known as Severe Acute Respiratory Syndrome (SARS), was identified in Hong Kong, China and a growing number of countries around the world in 2003. The invention relates to nucleic acids and proteins from the SARS coronavirus. These nucleic acids and proteins can be used in the preparation and manufacture of vaccine formulations, diagnostic reagents, kits, etc. The invention also provides methods for treating SARS by administering small molecule antiviral compounds, as well as methods of identifying potent small molecules for the treatment of SARS.
8.WO/2006/071896EPITOPE-BASED SARS VACCINE
WO 06.07.2006
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2005/047144 Applicant THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY Inventor GUO, Zhihong
This invention provides a vaccine for the infectious severe acute respiratory syndrome (SARS), which comprises antigenic epitopes from the pathogenic coronavirus. The antigenic epitopes were determined from the complementary antibodies in the plasma of convalescent SARS patients through phage display epitope mapping. These immunodominants consit of short peptide fragments distributed on various viral proteins, which includes, the spike protein, the nucleocapsid protein, the replicase 1a, and the unknown proteins 3a and 9b. Complementary antibodies targeting the immunodominant site on the spike protein effectively neutralize the coronavirus in vitro. This epitope-based vaccine avoids potential immunopathologic effects found in vaccines for other human or animal diseases since the epitopes induced safe and benificial humoral antibodies in convalescent SARS patients.
9.11054429SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein binding
US 06.07.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17220043 Applicant National University of Singapore Inventor Linfa Wang

A kit, composition and method for detection of antibodies to severe acute respiratory syndrome related coronavirus (SARSr-CoV), and for diagnosis of SARSr-CoV infection.

10.11103576Measles virus vaccine expressing SARS-COV-2 protein(s)
US 31.08.2021
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No 17010591 Applicant University of Pittsburgh—Of the Commonwealth System of Higher Education Inventor William Paul Duprex

A recombinant measles viral vector comprising a nucleic acid sequence encoding a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein is provided. Polypeptides comprising the SARS-CoV-2 spike glycoprotein also are provided, as well as related nucleic acids, vectors, and compositions. The polypeptides, nucleic acids, vectors, and compositions can be used in methods of preventing, inhibiting, reducing, eliminating, protecting, or delaying the onset of an infection or an infectious clinical condition caused by coronavirus and methods for inducing an immune response against a coronavirus.